Novi Invest provides early-stage health and medtech ventures and SMEs with the capital, strategy, and commercial know-how to turn breakthrough ideas into scalable businesses.
Our approach
Breakthroughs in health and life sciences are built through collaboration. Our approach combines smart early-stage funding with practical, hands-on support — from refining your strategy to helping you build the right team.Because we don’t just back ventures; we build the ecosystem around them.
Founder-first funding
We've lived founder mode for decades. We back people, not just business plans.
Strategic investments
We connect you with commercial insight, networks and mentoring opportunities.
Health & medtech focus
Deep expertise across diagnostics, digital health, devices, biotech and biopharmaceuticals
Collaborative by design
Working alongside investors, accelerators, and founders who share our belief in progress.
An investor that thinks like a founder.
We understand the challenges of turning scientific vision into commercial success. Unlike traditional investors, we work closely with our portfolio — helping you refine your proposition, assemble your team, and open doors that accelerate growth.
The NV advantage
Every investment we make is tailored to help founders scale faster and smarter. We focus on early-stage health and medtech ventures where our combination of capital, commercial experience, and recruitment strength creates outsized impact.
Seed
AI-Powered Early Cancer Detection
Supporting an advanced medical imaging AI company that develop certified AI tools that enable earlier detection of overlooked cancers from routine CT scans. They are looking to secure investment to support product expansion and commercial rollout across key markets. They have strong clinical validation, early commercial traction and a unique multi-organ approach in a rapidly growing sector.
Seed
Rapid NGS Oncology Diagnostics
The company delivers fast, affordable gene-expression testing with whole-transcriptome results available within 24 hours, compared to the standard 4–6 week turnaround. By addressing a major bottleneck in cancer care with unmatched speed and accuracy, the business is seeking investment to complete clinical validation, advance regulatory approval, and launch its decentralised diagnostic platform across leading oncology centres.
Ready to take your idea from lab to market?
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
